Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 12, 2009, Pages 2644-2648

  Kwon, Yong Dae ^a   Kim, Deog Yoon ^a   Ohe, Joo Young ^a   Yoo, Ji Yeon ^a   Walter, Christian ^b  

^a Kyung Hee University College of Medicine   (South Korea)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS LINKING; DISEASE CLASSIFICATION; FACE INJURY; FEMALE; HUMAN; JAW OSTEONECROSIS; MALE; OSTEOPOROSIS; RISK ASSESSMENT; STAGING; TOOTH DISEASE; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 71549140351     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.04.067     Document Type: Article

References (26)

1. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
2. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968
3. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
4. Rosen H.N., Moses A.C., Garber J., et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66 (2000) 100
5. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
6. Marx R.E. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws (2007), Quintessence, Miami, FL
7. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
8. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
9. Sarasquete M.E., Garcia-Sanz R., Marin L., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 112 (2008) 2709
10. Kwon Y.-D., Yoon B.-W., and Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery?. J Korean Assoc Maxillofac Plast Reconstr Surg 29 (2007) 456
11. Kwon Y.-D., Kim Y.-R., Choi B.-J., et al. Oral bisphosphonate related osteonecrosis of the jaws: Favorable outcome afterbisphosphonate holiday. Quintessence Int 40 (2009) 277
12. Lenz J.H., Steiner-Krammer B., Schmidt W., et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Cranio-Maxillofacial Surg 33 (2005) 395
13. Hess L.M., Jeter J.M., Benham-Hutchins M., et al. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 (2008) 475
14. Altundag K., Bulut N., Tezcan E., et al. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates?. J Oral Maxillofac Surg 65 (2007) 154
15. Bisdas S., Chambron Pinho N., Smolarz A., et al. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63 (2008) 71
16. Fink E., Cormier C., Steinmetz P., et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11 (2000) 295
17. Schwartz H.C. Serum CTX testing. J Oral Maxillofac Surg 66 (2008) 1319
18. Khosla S., Burr D., Cauley J., et al. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66 (2008) 1320
19. Bagan J.V., Jimenez Y., Gomez D., et al. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44 (2008) 1088
20. Kwon Y.-D., and Kim D.-Y. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 45 (2009) 839
21. Assael L.A. Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: Paths toward minimizing surgical risk?. J Oral Maxillofac Surg 65 (2007) 2395
22. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008) 733
23. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809
24. Grbic J.T., Landesberg R., Lin S.Q., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139 (2008) 32
25. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189
26. Lin J.H., Russell G., and Gertz B. Pharmacokinetics of alendronate: An overview. Int J Clin Pract Suppl 101 (1999) 18